The effect of compression on solid-state properties of desloratadine and multicomponent crystal

Abstract

Tablet pharmaceuticals manufacturing process involves several processes i.e. granulation, drying, milling, and compression. This study was conducted to determine the effect of compression of desloratadine (DES) and multicomponent crystal (MCC), which is a salt from DES, on their solid-state properties. A compression method for tablet formation was conducted using a hydraulic pressure machine with punch diameter of 13 mm. Both DES and MCC were made into tablets with the same tensile strength, which is 1.36 MPa. DES and MCC powder and tablet were each evaluated for their physicochemical properties, including analysis of powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and tablet dissolution. PXRD diffractogram analysis results on DES and MCC showed that the degree of crystallinity decreased after the compression process. There were no polymorphic transformation in DES and MCC after compression. DSC analysis showed a decrease of enthalpy after DES and MCC are compressed. FTIR showed the same spectra pattern for DES and MCC powder and tablet. The SEM scans showed a tendency for interparticle attachment in DES tablets and none in MCC tablets. Meanwhile, dissolution, as indicated by dissolution efficiency, is only slightly decreased due to the compression process. DES and MCC analysis, all characteristics indicated changes of physicochemical properties after compression pressure, but those changes did not affect their dissolution results.

Keywords

• Desloratadine
• multicomponent crystal
• compression
• solid-state properties
• dissolution

References

1. [1] Mazel V, Delplace C, Busignies V, Faivre V, Tchoreloff P, Yagoubi N. Polymorphic transformation of anhydrous caffeine under compression and grinding: a re-evaluation. Drug Dev Ind Pharm. 2011;37(7):832–840. [CrossRef]
2. [2] Patel S, Kaushal AM, Bansal AK. Compression physics in the formulation development of tablets. Crit Rev Ther Drug Carrier Syst. 2006;23(1):1–65. [CrossRef]
3. [3] Brittain HG. Effects of mechanical processing on phase composition. J Pharm Sci. 2002;91(7):1573–1580. [CrossRef]
4. [4] Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev. 2001;48(1):91–114. [CrossRef]
5. [5] Feng T, Pinal R, Carvajal MT. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci. 2008;97(8):3207–3221. [CrossRef]
6. [6] Bhadra S, Khastgir D. Determination of crystal structure of polyaniline and substituted polyanilines through powder X-ray diffraction analysis. Polym Test. 2008;27(7):851–857. [CrossRef]
7. [7] Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE, Williams SM, Greenfeder S, Billah M, Kreutner W, Egan RW. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002;449(3):229–237. [CrossRef]
8. [8] Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;107(4):751–762. [CrossRef]

9. [9] Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001;10(3):547–560. [CrossRef]
10. [10] Ainurofiq A, Mauludin R, Mudhakir D, Umeda D, Soewandhi SN, Putra OD, Yonemochi E. Improving mechanical properties of desloratadine via multicomponent crystal formation. Eur J Pharm Sci. 2018;111:65–72. [CrossRef]
11. [11] Ahmed H, Shimpi MR, Velaga SP. Relationship between mechanical properties and crystal structure in cocrystals and salt of paracetamol. Drug Dev Ind Pharm. 2017;43(1):89–97. [CrossRef]
12. [12] Chang S-Y, Sun CC. Superior Plasticity and Tabletability of Theophylline Monohydrate. Mol Pharm. 2017;14(6):2047–2055. [CrossRef]
13. [13] ter Laak AM, Tsai RS, Donné-Op den Kelder GM, Carrupt P-A, Testa B, Timmerman H. Lipophilicity and hydrogen-bonding capacity of H1-antihistaminic agents in relation to their central sedative side-effects. Eur J Pharm Sci. 1994;2(5):373–384. [CrossRef]
14. [14] Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi SN. Synthesis, characterization, and stability study of desloratadine multicomponent crystal formation. Res Pharm Sci. 2018;13(2):93–102. [CrossRef]
15. [15] Bernardi LS, Oliveira PR, Murakami FS, Silva M a. S, Borgmann SHM, Cardoso SG. Characterization of venlafaxine hydrochloride and compatibility studies with pharmaceutical excipients. J Therm Anal Calorim. 2009;97(2):729–733. [CrossRef]
16. [16] Kaneniwa N, Imagawa K, Otsuka M. Effect of Tabletting on the Degree of Crystallinity and on the Dehydration and Decomposition Points of Cephalexin Crystalline Powder. Chem Pharm Bull (Tokyo). 1985;33(2):802–809. [CrossRef]
17. [17] Lima MFS, Vasconcellos MAZ, Samios D. Crystallinity changes in plastically deformed isotactic polypropylene evaluated by x-ray diffraction and differential scanning calorimetry methods. J Polym Sci Part B Polym Phys. 2002;40(9):896–903. [CrossRef]
18. [18] Ek R, Wormald P, Iversen T, Nyström C. Crystallinity index of microcrystalline cellulose particles compressed into tablets. Int J Pharm. 1995;125(2):257–264. [CrossRef]
19. [19] Fukuoka E, Makita M, Yamamura S. Preferred Orientation of Crystallites in Tablets. III. Variations of Crystallinity and Crystallite Size of Pharmaceuticals with Compression. Chem Pharm Bull (Tokyo). 1993;41(3):595–598. [CrossRef]
20. [20] Brittain HG. Spectral methods for the characterization of polymorphs and solvates. J Pharm Sci. 1997;86(4):405–412. [CrossRef]
21. [21] Tajber L, Corrigan OI, Healy AM. Physicochemical evaluation of PVP–thiazide diuretic interactions in co-spray-dried composites—analysis of glass transition composition relationships. Eur J Pharm Sci. 2005;24(5):553–563. [CrossRef]
22. [22] Tedesco E, Giron D, Pfeffer S. Crystal structure elucidation and morphology study of pharmaceuticals in development. CrystEngComm. 2002;4(67):393–400. [CrossRef]
23. [23] Wang QB, Wang QG, Wan CX. Effect of sintering time on the microstructure and properties of inorganic polyphosphate bioceramics. Sci Sinter. 2010;42(3):337–343. [CrossRef]
24. [24] Riippi M, Yliruusi J, Niskanen T, Kiesvaara J. Dependence between dissolution rate and porosity of compressed erythromycin acistrate tablets. Eur J Pharm Biopharm. 1998;46(2):169–175. [CrossRef]
25. [25] Suzuki T, Nakagami H. Effect of crystallinity of microcrystalline cellulose on the compactability and dissolution of tablets. Eur J Pharm Biopharm. 1999;47(3):225–230. [CrossRef]